Penn Medicine Lancaster General Health’s Ann B. Barshinger Cancer Institute now offers the advanced cancer treatment CAR T-cell immunotherapy, a groundbreaking immunotherapy treatment that was developed at Penn Medicine in Philadelphia.
CAR T (Chimeric Antigen Receptor T-Cell) is a type of cancer therapy that uses specially modified immune cells from a patient’s own body. T-cells, a type of white blood cell, are removed from the patient and reprogrammed to find and attack cancer cells when reinfused into the bloodstream.
Penn Medicine is a global leader in immunotherapy research that expands the safety and effectiveness of CAR T. CAR T was the first gene therapy to be approved by the Food and Drug Administration (FDA) and has brought a new era of cancer treatment options.
CAR T-cell therapy is used to treat patients with certain kinds of aggressive blood cancers that have not responded to one or more therapies, such as large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.
For more information on CAR T-cell therapy, please visit our website lghealth.org.
Find our contact forms and phone numbers or give feedback on a recent experience using Care to Share.
View test results, schedule appointments, or request prescription refills from the convenience of your computer or mobile device.
Learn about health system news and meet new providers in Progress Notes, Lancaster General Health's provider newsletter.
Want to make a payment without a MyLGHealth account? Click the "Pay as Guest" button below.